MX2023002367A - Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met. - Google Patents

Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met.

Info

Publication number
MX2023002367A
MX2023002367A MX2023002367A MX2023002367A MX2023002367A MX 2023002367 A MX2023002367 A MX 2023002367A MX 2023002367 A MX2023002367 A MX 2023002367A MX 2023002367 A MX2023002367 A MX 2023002367A MX 2023002367 A MX2023002367 A MX 2023002367A
Authority
MX
Mexico
Prior art keywords
met antibody
stable formulations
pharmaceutical compositions
bispecific egfr
aqueous pharmaceutical
Prior art date
Application number
MX2023002367A
Other languages
English (en)
Inventor
Jessica Kupec
Melissa Schreyer
Patrick Stahl
Satyen Torne
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023002367A publication Critical patent/MX2023002367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente descripción se proporcionan composiciones farmacéuticas acuosas estables que comprenden formulaciones de un anticuerpo biespecífico para el receptor del factor de crecimiento epidérmico (EGFR)/receptor del factor de crecimiento de hepatocitos (c-Met) y métodos para prepararlas. También se proporcionan en la presente descripción métodos para tratar el cáncer en un sujeto que lo necesita al administrar al sujeto la composición farmacéutica acuosa estable como se describe en la presente descripción. Además, en la presente descripción se proporcionan kits y artículos de fabricación que comprenden las composiciones farmacéuticas acuosas estables como se describe en la presente descripción.
MX2023002367A 2020-08-26 2021-08-26 Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met. MX2023002367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070440P 2020-08-26 2020-08-26
PCT/IB2021/057802 WO2022043900A1 (en) 2020-08-26 2021-08-26 Stable formulations comprising a bispecific egfr/c-met antibody

Publications (1)

Publication Number Publication Date
MX2023002367A true MX2023002367A (es) 2023-05-22

Family

ID=80352835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002367A MX2023002367A (es) 2020-08-26 2021-08-26 Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met.

Country Status (16)

Country Link
US (1) US20220064307A1 (es)
EP (1) EP4204456A1 (es)
JP (1) JP2023540025A (es)
KR (1) KR20230057400A (es)
CN (1) CN116194485A (es)
AR (2) AR123340A1 (es)
AU (1) AU2021333882A1 (es)
BR (1) BR112023003373A2 (es)
CA (1) CA3192630A1 (es)
CR (1) CR20230102A (es)
EC (1) ECSP23013655A (es)
IL (1) IL300895A (es)
MX (1) MX2023002367A (es)
PE (1) PE20231370A1 (es)
TW (1) TW202227129A (es)
WO (1) WO2022043900A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2024003837A1 (en) 2022-06-30 2024-01-04 Janssen Biotech, Inc. Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053553A1 (es) * 2005-03-08 2007-05-09 Pharmacia & Upjohn Co Llc Composicion de anticuerpos anti molecula de adhesion celular adresina mucosa (anti-madcam)
SI2922872T1 (sl) * 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET

Also Published As

Publication number Publication date
AR123340A1 (es) 2022-11-23
CN116194485A (zh) 2023-05-30
KR20230057400A (ko) 2023-04-28
AU2021333882A9 (en) 2023-07-13
PE20231370A1 (es) 2023-09-07
CR20230102A (es) 2023-06-23
ECSP23013655A (es) 2023-03-31
US20220064307A1 (en) 2022-03-03
AU2021333882A1 (en) 2023-05-11
BR112023003373A2 (pt) 2023-04-11
EP4204456A1 (en) 2023-07-05
JP2023540025A (ja) 2023-09-21
TW202227129A (zh) 2022-07-16
AR124067A2 (es) 2023-02-08
IL300895A (en) 2023-04-01
CA3192630A1 (en) 2022-03-03
WO2022043900A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2023002367A (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2021011242A (es) Conjugados de vesícula extracelular y usos de estos.
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
RU2013146469A (ru) Антитела к her
WO2012143495A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
TW200519104A (en) Quinazoline derivatives
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
MY199042A (en) Aminopyrimidine compound, preparation method therefor and use thereof
US20230372287A1 (en) Isoflavonoid compounds and methods for the treatment of cancer
MX2023004937A (es) Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.
ECSP23080283A (es) Formulaciones de anticuerpos biespecíficos de alta concentración
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
MX2020010290A (es) Composiciones anestesicas de liberacion sostenida y metodos de preparacion de las mismas.
BR112022020482A2 (pt) Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
MX2021013391A (es) Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo.
PE20221005A1 (es) Derivados de la camptotecina
MX2020002266A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.